STAT+: FDA, CMS scramble to avoid regulatory logjam as more states look to test AI in clinical settings
Reported by STAT News · all stories from statnews.com
Editorial digest
Federal regulators at FDA and CMS are attempting to resolve potential procedural bottlenecks before states launch clinical artificial intelligence trials. The agencies aim to align regional testing plans with existing national healthcare standards.
Digests are written in our own words from the publisher's headline — we never reproduce article text. Read the original for the full reporting.
Read the full story at STAT News →More like this
Other stories our editors tagged with the same themes.
- Trusted health newsroom10/22/2026
STAT+: Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction
Virtual clinics are providing off-label GLP-1 therapies for substance use disorders before receiving formal regulatory authorization.
- Trusted health newsroom10/5/2026
STAT+: Utah plows ahead with more health AI pilots for prescriptions, women’s health
Utah continues expanding health AI pilot programs for prescriptions and women's health.
- Trusted health newsroom10/8/2026
STAT+: AI for breast cancer risk prediction goes DTC, regulatory cloud over Utah sandbox, and AI psychosis
AI for breast cancer risk is now direct-to-consumer; regulatory concerns and AI-induced psychosis are also discussed.
- Trusted health newsroom10/15/2026
Opinion: MyChart said I could opt out of sharing my health data. Figuring out how was maddening
An opinion piece describes difficulties in opting out of health data sharing through MyChart.
- Trusted health newsroom9/3/2026
STAT+: FDA pilot offers generative AI medical devices a path to patients before they are authorized
FDA pilot program allows generative AI devices to reach patients pre-authorization.
- Trusted health newsroom8/25/2026
STAT+: FDA promises new AI guidance, and what happened at Epic’s UGM
The FDA will issue new AI regulations; Epic's user meeting also had significant updates.